Vetoquinol is pleased to announce the creation of the: Vetoquinol Mobility Program Clinical Study Grant.
The Vetoquinol Mobility Program (VMP) is a comprehensive method of multimodal osteoarthritis management in dogs and cats combining both pharmaceutical and non-pharmaceutical solutions in order to provide pain relief, improved quality of life and return to function.
The 3 principal components of the VMP include:
Cimalgex®, a Cox-II specific NSAID for acute and chronic pain relief in dogs
Flexadin Advanced®, a nutritional supplement containing undenatured Type-II collagen which has been shown to reduce inflammation by a mechanism called oral tolerance
Veterinary rehabilitation therapy to both diminish pain and improve function
The VMP Clinical Study Grant Program is aimed at supporting research which will demonstrate the clinical use of one or more of the principal components of the program.
Applicants must be a veterinarian either with or in the process of obtaining an advanced degree. Proposals that include interns, residents or graduate students must have a sponsor in a faculty position or postdoctoral career appointment at the same institute
Proposals will be submitted using the format below and will be evaluated based upon the scientific interest of the research and the feasibility of timely completion and publication
The maximum award available for each study is 50 000 Euros
Maximum time for completion of the study is two years
The primary aim of the award is to publish the research in a peer-reviewed veterinary journal
Investigators will comply with all local ethical requirements
Reports of progress will be made every six months
Vetoquinol will be acknowledged in any publication
The selection committee for 2018 is chaired by Dr. Felix Duerr, Dr. med. vet., MS, Diplomate, American and European College of Veterinary Surgeons and American College of Veterinary Sports Medicine and Rehabilitation, Associate Professor of Small Animal Sports Medicine/Rehabilitation and Orthopedics at Colorado State University. The remainder of the Committee will be composed of Vetoquinol personnel across divisions and disciplines based on the relevance of the research proposed. Vetoquinol may use other academic consultants under confidentiality agreements to help with the review process.
Research grant(s) that centers on the clinical use of one or more of the principal components of the program can be funded for up to a total of 50 000 Euros.
The objective of the Grant Program is to fund research for management of osteoarthritis which will result in publication in a peer reviewed veterinary journal. Research Study proposals will be evaluated based upon the scientific interest of the research and the feasibility of timely completion and publication.
It is expressly understood and agreed by the Candidates and particularly the Winner(s) that any patentable results of the Research Study will be solely owned by VETOQUINOL which shall alone decide to file patent application based on said results. In the event that the filing of a patent application is being contemplated by VETOQUINOL any publication or communication related to the results shall be deferred upon VETOQUINOL’s mere request, which deferral shall last until the application is published.
A budget should be included with divisions by major categories of expense if possible (e.g. animal care, laboratory assays, purchase of study drug…). Itemized budgets will be required if the project is selected for funding. The maximum budget amount is 50,000 Euros. Residual funds will be required to be returned at the end of (2) years. The VMP grant will NOT pay for full-time faculty salaries, the purchase of laboratory equipment, or overhead fees
The timeline should be included with appropriate major milestones.
Deadline for submission: 2018, October 1st
Results of grant allocation: 2018, December